V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20214731 | 20080970 | 1.7 | 72.5 | null | 2016-07-30 | 2016-07-30 | LANREOTIDE | 02 | Y | LANREOTIDE | 100685053 |
| 20214732 | 20080971 | null | 79.6 | Palliative (P) | 2017-07-28 | 2017-08-22 | LANREOTIDE | 02 | N | LANREOTIDE | 100943885 |
| 20214733 | 20080972 | 1.6 | 65 | null | 2020-12-13 | 2020-12-13 | LANREOTIDE | 02 | null | LANREOTIDE | 100336754 |
| 20214734 | 20080973 | 1.73 | 75.7 | Palliative (P) | 2017-07-29 | 2017-08-10 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100848072 |
| 20214735 | 20080974 | 1.83 | 99.5 | Palliative (P) | 2019-05-03 | 2019-05-17 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100044984 |
| 20214736 | 20080975 | 1.53 | 55 | Palliative (P) | 2018-03-30 | 2018-04-13 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101128271 |
| 20214738 | 20080977 | 1.49 | 80.7 | Palliative (P) | 2019-09-21 | 2019-09-22 | Trial Unspecified | Y | N | TRIAL | 100015144 |
| 20214739 | 20080978 | null | 88.5 | null | 2022-03-05 | 2022-04-06 | LANREOTIDE | 02 | N | LANREOTIDE | 100943144 |
| 20214740 | 20080979 | 1.65 | 65 | Curative (C) | 2019-02-16 | 2019-03-17 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 101585486 |
| 20214742 | 20080980 | 1.68 | 64 | Neo-adjuvant (N) | 2019-04-10 | 2019-04-10 | IMATINIB | 02 | N | IMATINIB | 100344344 |
| 20214743 | 20080981 | 1.78 | 103.3 | Curative (C) | 2019-02-17 | 2019-03-01 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | null | FLUOROURACIL + MITOMYCIN + RT | 100080495 |
| 20214744 | 20080982 | 1.57 | 116 | Palliative (P) | 2016-03-25 | 2016-04-13 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100875948 |
| 20214745 | 20080983 | 1.54 | 0 | Palliative (P) | 2018-10-01 | 2018-10-13 | HCX | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100042697 |
| 20214746 | 20080984 | 1.5 | 94.6 | Adjuvant (A) | 2016-05-22 | 2016-05-27 | CAPECITABINE + CISPLATIN + Trastuzumab | 99 | N | IMATINIB | 101587445 |
| 20214747 | 20080985 | 1.79 | 50.4 | Palliative (P) | 2016-04-12 | 2016-04-12 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 100230578 |
| 20214748 | 20080986 | 1.85 | 68.8 | Palliative (P) | 2020-06-22 | 2020-06-22 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101311090 |
| 20214749 | 20080987 | 1.59 | 84.2 | Palliative (P) | 2018-04-11 | 2018-04-25 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100828400 |
| 20214750 | 20080988 | 1.64 | 89 | Curative (C) | 2018-01-27 | 2018-02-10 | HCX (Cape + Cisp + Tras) - Load | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100101174 |
| 20214751 | 20080989 | 1.67 | 66.8 | Palliative (P) | 2016-10-04 | 2016-10-18 | Cape+Cisplatin+Trastuzumab Load | 02 | Y | TRIAL | 101106738 |
| 20214752 | 20080990 | 1.64 | 65 | null | 2017-12-07 | 2017-12-14 | LANREOTIDE | N | null | LANREOTIDE | 101586963 |
| 20214753 | 20080991 | 1.7 | 86.3 | Palliative (P) | 2017-05-23 | 2017-06-05 | Trial Unspecified | Y | N | TRIAL | 101057540 |
| 20214754 | 20080992 | null | 59 | Neo-adjuvant (N) | 2017-04-09 | 2017-04-09 | IMATINIB | 02 | N | IMATINIB | 101533914 |
| 20214756 | 20080993 | 1.74 | 62 | null | 2022-01-12 | 2022-01-19 | LANREOTIDE | 02 | null | LANREOTIDE | 100932363 |
| 20214757 | 20080994 | 1.8 | null | Curative (C) | 2017-09-07 | 2017-09-28 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101362762 |
| 20214758 | 20080995 | 1.63 | 83 | Palliative (P) | 2017-02-19 | 2017-03-02 | HCX | 02 | N | IMATINIB | 101584995 |
| 20214759 | 20080996 | 1.76 | 73.1 | Curative (C) | 2018-12-22 | 2019-01-25 | FLUOROURACIL + MITOMYCIN + RT | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 100127898 |
| 20214760 | 20080997 | 1.72 | 73.2 | Palliative (P) | null | 2016-12-04 | HCX | 02 | N | TRIAL | 101693353 |
| 20214761 | 20080998 | 1.75 | 60.4 | Palliative (P) | 2020-10-02 | 2020-10-07 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101283466 |
| 20214762 | 20080999 | 1.85 | 76.3 | Palliative (P) | 2018-07-03 | 2018-07-22 | IMATINIB | 2 | N | IMATINIB | 100886212 |
| 20214763 | 20081000 | 1.72 | 85.7 | Palliative (P) | 2017-11-29 | 2017-12-19 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101470973 |
| 20214764 | 20081001 | 1.71 | 60 | Palliative (P) | 2022-02-21 | 2022-03-02 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101579208 |
| 20214765 | 20081002 | 1.75 | 71.8 | Curative (C) | 2016-09-02 | 2016-09-20 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100931637 |
| 20214766 | 20081003 | 1.66 | 76.3 | Curative (C) | 2019-08-26 | 2019-09-14 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100691289 |
| 20214767 | 20081004 | 1.79 | 83.5 | Palliative (P) | 2016-04-18 | 2016-05-02 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100666150 |
| 20214768 | 20081005 | 1.71 | 124 | Neo-adjuvant (N) | 2017-01-24 | 2017-01-24 | IMATINIB | 02 | N | IMATINIB | 100846272 |
| 20214769 | 20081006 | 1.85 | 73.5 | Curative (C) | 2019-07-11 | 2019-07-11 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100119992 |
| 20214770 | 20081007 | 1.86 | null | Curative (C) | 2019-05-28 | 2019-06-04 | Fluorouracil+Mitomycin+RT (Anal Ca) | null | Y | FLUOROURACIL + MITOMYCIN + RT | 101565793 |
| 20214771 | 20081008 | 1.53 | 66 | Palliative (P) | null | null | HCX | 02 | N | IMATINIB | 100555278 |
| 20214772 | 20081009 | 1.8 | 0 | Curative (C) | 2019-11-21 | 2019-12-17 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 100270949 |
| 20214773 | 20081010 | null | 87.8 | Adjuvant (A) | 2018-11-08 | 2018-11-29 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 101367434 |
| 20214774 | 20081011 | null | 73.6 | 03 | 2017-10-26 | 2017-11-07 | Cape+Cisplatin+Trastuzumab Load | 02 | N | LANREOTIDE | 100534976 |
| 20214775 | 20081012 | 1.73 | 103 | Curative (C) | 2016-12-12 | 2017-01-03 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | null | FLUOROURACIL + MITOMYCIN + RT | 101315889 |
| 20214777 | 20081013 | 1.69 | 0 | null | 2016-06-12 | 2016-06-12 | LANREOTIDE | 02 | N | LANREOTIDE | 100613873 |
| 20214778 | 20081014 | 1.8 | 55.2 | Palliative (P) | 2017-07-06 | 2017-07-06 | IMATINIB | 02 | N | IMATINIB | 101636873 |
| 20214779 | 20081015 | 1.7 | 77 | Palliative (P) | 2018-05-24 | 2018-06-11 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100827230 |
| 20214780 | 20081016 | 1.82 | 75.4 | Palliative (P) | 2016-07-16 | 2016-07-16 | Trial Unspecified | 1 | N | TRIAL | 101105937 |
| 20214781 | 20081017 | 0 | 58 | 02 | 2016-02-05 | 2016-03-05 | LANREOTIDE | 02 | N | LANREOTIDE | 101186033 |
| 20214782 | 20081018 | 1.83 | 71.5 | null | 2019-04-28 | 2019-05-05 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101008543 |
| 20214783 | 20081019 | 1.8 | 91.2 | Curative (C) | 2018-05-16 | 2018-05-23 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101107484 |
| 20214784 | 20081020 | 1.61 | 71.8 | Disease modification (D) | 2017-02-27 | 2017-03-20 | HCX | 02 | N | LANREOTIDE | 100008374 |